ARDX Long Put Strategy
ARDX (Ardelyx, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients.
ARDX (Ardelyx, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.37B, a beta of 0.58 versus the broader market, a 52-week range of 3.74-8.4, average daily share volume of 3.8M, a public-listing history dating back to 2014, approximately 395 full-time employees. These structural characteristics shape how ARDX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.58 indicates ARDX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on ARDX?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current ARDX snapshot
As of June 30, 2026, spot at $5.05, ATM IV 25.60%, IV rank 6.10%, expected move 7.34%. The long put on ARDX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on ARDX specifically: ARDX IV at 25.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a ARDX long put, with a market-implied 1-standard-deviation move of approximately 7.34% (roughly $0.37 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARDX expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARDX should anchor to the underlying notional of $5.05 per share and to the trader's directional view on ARDX stock.
ARDX long put setup
The ARDX long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARDX near $5.05, the first option leg uses a $5.05 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARDX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARDX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $5.05 | N/A |
ARDX long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
ARDX long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on ARDX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on ARDX
Long puts on ARDX hedge an existing long ARDX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ARDX exposure being hedged.
ARDX thesis for this long put
The market-implied 1-standard-deviation range for ARDX extends from approximately $4.68 on the downside to $5.42 on the upside. A ARDX long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long ARDX position with one put per 100 shares held. Current ARDX IV rank near 6.10% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ARDX at 25.60%. As a Healthcare name, ARDX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARDX-specific events.
ARDX long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARDX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARDX alongside the broader basket even when ARDX-specific fundamentals are unchanged. Long-premium structures like a long put on ARDX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ARDX chain quotes before placing a trade.
Frequently asked questions
- What is a long put on ARDX?
- A long put on ARDX is the long put strategy applied to ARDX (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With ARDX stock trading near $5.05, the strikes shown on this page are snapped to the nearest listed ARDX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ARDX long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the ARDX long put priced from the end-of-day chain at a 30-day expiry (ATM IV 25.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ARDX long put?
- The breakeven for the ARDX long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ARDX market-implied 1-standard-deviation expected move is approximately 7.34%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on ARDX?
- Long puts on ARDX hedge an existing long ARDX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ARDX exposure being hedged.
- How does current ARDX implied volatility affect this long put?
- ARDX ATM IV is at 25.60% with IV rank near 6.10%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.